14,200 Shares in Progyny, Inc. (NASDAQ:PGNY) Purchased by Aristides Capital LLC

Aristides Capital LLC acquired a new stake in Progyny, Inc. (NASDAQ:PGNY) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 14,200 shares of the company’s stock, valued at approximately $245,000.

Other large investors have also made changes to their positions in the company. Atika Capital Management LLC purchased a new stake in Progyny in the 4th quarter worth $5,727,000. Aviva PLC increased its stake in shares of Progyny by 30.8% during the fourth quarter. Aviva PLC now owns 41,287 shares of the company’s stock worth $712,000 after purchasing an additional 9,721 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Progyny by 37.8% during the 4th quarter. Wells Fargo & Company MN now owns 39,593 shares of the company’s stock worth $683,000 after purchasing an additional 10,856 shares during the last quarter. Landscape Capital Management L.L.C. lifted its stake in Progyny by 109.2% in the 4th quarter. Landscape Capital Management L.L.C. now owns 349,614 shares of the company’s stock valued at $6,031,000 after buying an additional 182,457 shares in the last quarter. Finally, Bryce Point Capital LLC acquired a new stake in Progyny in the 4th quarter worth about $353,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. BTIG Research raised Progyny from a “neutral” rating to a “buy” rating and set a $28.00 target price for the company in a report on Monday, March 31st. JPMorgan Chase & Co. increased their price objective on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Bank of America upped their target price on shares of Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. Finally, Canaccord Genuity Group raised their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research note on Friday, February 28th. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Progyny currently has an average rating of “Hold” and an average target price of $23.64.

Progyny Stock Performance

PGNY stock opened at $22.60 on Monday. The firm has a market cap of $1.93 billion, a PE ratio of 38.97, a PEG ratio of 2.39 and a beta of 1.33. Progyny, Inc. has a one year low of $13.39 and a one year high of $36.36. The firm’s 50 day moving average price is $22.19 and its 200-day moving average price is $18.45.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.